Seventy-six items achieved consensus, including indications for LDOM versus topical minoxidil, dosing for adults and teens, contraindications ...

Miplyffa was approved in September 2024 based on data from a clinical trial that showed arimoclomol plus miglustat slowed NPC disease progression.

Credit: Endo, Inc At this time, there have been no reports of adverse events related to this recall. While the blister strips ...

Maternal vaccination two to three or three to four weeks before delivery linked to lower cord:maternal transfer ratios versus at least five weeks ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...

(HealthDay News) — Based on the current trajectory, overweight and obesity will continue increasing in the United States up to 2050, according to a study published online Nov. 14 in The Lancet.

The BLA approval is supported by data from the COBLT study, FDA dockets and public information, and from a RegeneCyte observational database.

In three databases, 4.5, 6.0, and 6.2 percent of medically attended RSV patients experienced 28-day all-cause hospitalization ...

Risk increased with worsening CKD stage with denosumab versus bisphosphonates; highest risk seen for dialysis-dependent CKD, CKD-mineral and bone disorder ...

Source: Getty Images “The potential adverse impact of chemotherapy exposure during pregnancy is likely mediated through ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Treatment with liberixibat led to a statistically significant improvement in itch compared with placebo. Topline results were announced from a phase 3 trial evaluating linerixibat for the ...